current *Haemophilus influenzae* type b conjugate vaccines have no protective effect against nontypeable strains.

The technologies described herein are conjugate vaccines against nontypeable *Haemophilus influenzae*. The vaccines are comprised of lipooligosaccharides (LOS) from which esterified fatty acids have been removed from lipid A to form detoxified LOS conjugated to an immunogenic carrier such as tetanus toxoid, and an adjuvant such as alum. *In vivo* data in the Chinchilla animal model are available. The vaccines can be potentially used as a component in a combination vaccine with other pediatric vaccine components.

**Applications:** Vaccines for the prevention of respiratory infections and otitis media caused by nontypeable *Haemophilus influenzae*.  
**Advantages:**  
- Novel vaccine candidates.  
- Conserved antigen.

**Development Status:** *In vitro* and *in vivo* data can be provided upon request. Data is also available from a phase I clinical trial with a representative vaccine showing safety and immunogenicity in adults.  
**Market:**  
- Pediatric vaccines.  
- Preventative vaccines.

**Inventors:** Xin-xing Gu (NIDCD), John Robbins (NICHD), et al.

**Related Publication:** W Hong et al.


**Patent Status:**  

**Licensing Status:** Available for licensing.

**Licensing Contact:** Kevin W. Chang, Ph.D.; 301–435–5018; changke@mail.nih.gov.

**Collaborative Research Opportunity:** The National Institute on Deafness and Other Communication Disorders, Vaccine Research Section, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize the subject technology. Please contact Brian W. Bailey, Ph.D. at 301–594–4094 or bbailey@mail.nih.gov for more information.

**Richard U. Rodriguez,**  
Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

**National Cancer Institute; Notice of Closed Meetings**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meetings. The meetings will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

**Name of Committee:** National Cancer Institute Special Emphasis Panel, T32 Review.

**Date:** May 11, 2010.  
**Time:** 5 p.m. to 6 p.m.  
**Agenda:** To review and evaluate grant applications.

**Place:** Hilton Crystal City, 2399 Jefferson Davis Hwy, Arlington, VA 22202.

**Contact Person:** Robert Bird, PhD, Chief, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Boulevard, Room 8113, Bethesda, MD 20892–8328, 301–496–7978, birdr@mail.nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel, Epidemiology, Prevention, Control and Population Sciences.

**Date:** May 26–27, 2010.  
**Time:** 8 a.m. to 5 p.m.  
**Agenda:** To review and evaluate grant applications.

**Place:** Hilton Washington DC/Rockville, Rockville, MD 20852.

**Contact Person:** Wlodz Lopaczynski, M.D., PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8131, Bethesda, MD 20892, 301–594–1402, lopacz@mail.nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel, Cellular & Tissue Biology PO1.

**Date:** May 26–28, 2010.  
**Time:** 5 p.m. to 5 p.m.  
**Agenda:** To review and evaluate grant applications.

Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, Bethesda, MD 20852.

**Contact Person:** Shakeel Ahmad, PhD, Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 6116 Executive Boulevard, Room 8139, Bethesda, MD 20892–8328, (301) 594–0114, ahmads@mail.nih.gov.

**Name of Committee:** National Cancer Institute Special Emphasis Panel, State and Community Tobacco Control Policy and Media Research.

**Date:** May 26–27, 2010.  
**Time:** 7 p.m. to 5 p.m.  
**Agenda:** To review and evaluate grant applications.

Place: Legacy Hotel and Conference Center, 1775 Rockville Pike, Rockville, MD 20852.

**Contact Person:** Gerald G. Lovinger, PhD, Scientific Review Officer, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, 6116 Executive Blvd., Room 8101, Bethesda, MD 20892–8329, 301/496–7987, lovimgeg@mail.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)


Jennifer Spaeth,  
Director, Office of Federal Advisory Committee Policy.

**DEPARTMENT OF HEALTH AND HUMAN SERVICES**

**National Institutes of Health**

**Office of the Director, National Institutes of Health; Notice of Closed Meeting**

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant application, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.